Selected research
Market Structure
Global Gastrointestinal Cancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Gastrointestinal Cancer Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Gastrointestinal Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Gastrointestinal Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Gastrointestinal Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Gastrointestinal Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Gastrointestinal Cancer Drugs include Sanofi, Johnson & Johnson Private, Novartis, Roche, Eli Lilly and Company, Pfizer, GlaxoSmithKline, Bristol-Myers Squibb Company and Celgene Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Gastrointestinal Cancer Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Gastrointestinal Cancer Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Gastrointestinal Cancer Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Gastrointestinal Cancer Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Gastrointestinal Cancer Drugs Segment by Company
Sanofi
Johnson & Johnson Private
Novartis
Roche
Eli Lilly and Company
Pfizer
GlaxoSmithKline
Bristol-Myers Squibb Company
Celgene Corporation
Amgen & Amgen Ireland
Gastrointestinal Cancer Drugs Segment by Type
Oncology
Radiology
Others
Gastrointestinal Cancer Drugs Segment by Application
Specialized Cancer Treatment Centers
Clinics
Hospitals
Ambulatory Surgical Centers
Gastrointestinal Cancer Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastrointestinal Cancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gastrointestinal Cancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastrointestinal Cancer Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Gastrointestinal Cancer Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gastrointestinal Cancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Gastrointestinal Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Gastrointestinal Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Oncology
- Radiology
- Others
Applications
- Specialized Cancer Treatment Centers
- Clinics
- Hospitals
- Ambulatory Surgical Centers
Companies covered
- Sanofi
- Johnson & Johnson Private
- Novartis
- Roche
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Bristol-Myers Squibb Company
- Celgene Corporation
- Amgen & Amgen Ireland
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Gastrointestinal Cancer Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Gastrointestinal Cancer Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Gastrointestinal Cancer Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Gastrointestinal Cancer Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Gastrointestinal Cancer Drugs Market Dynamics
- 2.1 Gastrointestinal Cancer Drugs Industry Trends
- 2.2 Gastrointestinal Cancer Drugs Industry Drivers
- 2.3 Gastrointestinal Cancer Drugs Industry Opportunities and Challenges
- 2.4 Gastrointestinal Cancer Drugs Industry Restraints
3 Gastrointestinal Cancer Drugs Market by Manufacturers
- 3.1 Global Gastrointestinal Cancer Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Gastrointestinal Cancer Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Gastrointestinal Cancer Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Gastrointestinal Cancer Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Gastrointestinal Cancer Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Gastrointestinal Cancer Drugs Manufacturers, Product Type & Application
- 3.7 Global Gastrointestinal Cancer Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Gastrointestinal Cancer Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Gastrointestinal Cancer Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Gastrointestinal Cancer Drugs Tier 1, Tier 2, and Tier 3
4 Gastrointestinal Cancer Drugs Market by Type
- 4.1 Gastrointestinal Cancer Drugs Type Introduction
- 4.1.1 Oncology
- 4.1.2 Radiology
- 4.1.3 Others
- 4.2 Global Gastrointestinal Cancer Drugs Sales by Type
- 4.2.1 Global Gastrointestinal Cancer Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Gastrointestinal Cancer Drugs Sales by Type (2021-2032)
- 4.2.3 Global Gastrointestinal Cancer Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Gastrointestinal Cancer Drugs Revenue by Type
- 4.3.1 Global Gastrointestinal Cancer Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Gastrointestinal Cancer Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Gastrointestinal Cancer Drugs Revenue Market Share by Type (2021-2032)
5 Gastrointestinal Cancer Drugs Market by Application
- 5.1 Gastrointestinal Cancer Drugs Application Introduction
- 5.1.1 Specialized Cancer Treatment Centers
- 5.1.2 Clinics
- 5.1.3 Hospitals
- 5.1.4 Ambulatory Surgical Centers
- 5.2 Global Gastrointestinal Cancer Drugs Sales by Application
- 5.2.1 Global Gastrointestinal Cancer Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Gastrointestinal Cancer Drugs Sales by Application (2021-2032)
- 5.2.3 Global Gastrointestinal Cancer Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Gastrointestinal Cancer Drugs Revenue by Application
- 5.3.1 Global Gastrointestinal Cancer Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Gastrointestinal Cancer Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Gastrointestinal Cancer Drugs Revenue Market Share by Application (2021-2032)
6 Global Gastrointestinal Cancer Drugs Sales by Region
- 6.1 Global Gastrointestinal Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Gastrointestinal Cancer Drugs Sales by Region (2021-2032)
- 6.2.1 Global Gastrointestinal Cancer Drugs Sales by Region (2021-2026)
- 6.2.2 Global Gastrointestinal Cancer Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Gastrointestinal Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Gastrointestinal Cancer Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Gastrointestinal Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Gastrointestinal Cancer Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Gastrointestinal Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Gastrointestinal Cancer Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Gastrointestinal Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Gastrointestinal Cancer Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Gastrointestinal Cancer Drugs Revenue by Region
- 7.1 Global Gastrointestinal Cancer Drugs Revenue by Region
- 7.1.1 Global Gastrointestinal Cancer Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Gastrointestinal Cancer Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Gastrointestinal Cancer Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Gastrointestinal Cancer Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Gastrointestinal Cancer Drugs Revenue (2021-2032)
- 7.2.2 North America Gastrointestinal Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Gastrointestinal Cancer Drugs Revenue (2021-2032)
- 7.3.2 Europe Gastrointestinal Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Gastrointestinal Cancer Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Gastrointestinal Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Gastrointestinal Cancer Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Gastrointestinal Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Sanofi
- 8.1.1 Sanofi Company Information
- 8.1.2 Sanofi Business Overview
- 8.1.3 Sanofi Gastrointestinal Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Sanofi Gastrointestinal Cancer Drugs Product Portfolio
- 8.1.5 Sanofi Recent Developments
- 8.2 Johnson & Johnson Private
- 8.2.1 Johnson & Johnson Private Company Information
- 8.2.2 Johnson & Johnson Private Business Overview
- 8.2.3 Johnson & Johnson Private Gastrointestinal Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Johnson & Johnson Private Gastrointestinal Cancer Drugs Product Portfolio
- 8.2.5 Johnson & Johnson Private Recent Developments
- 8.3 Novartis
- 8.3.1 Novartis Company Information
- 8.3.2 Novartis Business Overview
- 8.3.3 Novartis Gastrointestinal Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Novartis Gastrointestinal Cancer Drugs Product Portfolio
- 8.3.5 Novartis Recent Developments
- 8.4 Roche
- 8.4.1 Roche Company Information
- 8.4.2 Roche Business Overview
- 8.4.3 Roche Gastrointestinal Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Roche Gastrointestinal Cancer Drugs Product Portfolio
- 8.4.5 Roche Recent Developments
- 8.5 Eli Lilly and Company
- 8.5.1 Eli Lilly and Company Company Information
- 8.5.2 Eli Lilly and Company Business Overview
- 8.5.3 Eli Lilly and Company Gastrointestinal Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Eli Lilly and Company Gastrointestinal Cancer Drugs Product Portfolio
- 8.5.5 Eli Lilly and Company Recent Developments
- 8.6 Pfizer
- 8.6.1 Pfizer Company Information
- 8.6.2 Pfizer Business Overview
- 8.6.3 Pfizer Gastrointestinal Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Pfizer Gastrointestinal Cancer Drugs Product Portfolio
- 8.6.5 Pfizer Recent Developments
- 8.7 GlaxoSmithKline
- 8.7.1 GlaxoSmithKline Company Information
- 8.7.2 GlaxoSmithKline Business Overview
- 8.7.3 GlaxoSmithKline Gastrointestinal Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 GlaxoSmithKline Gastrointestinal Cancer Drugs Product Portfolio
- 8.7.5 GlaxoSmithKline Recent Developments
- 8.8 Bristol-Myers Squibb Company
- 8.8.1 Bristol-Myers Squibb Company Company Information
- 8.8.2 Bristol-Myers Squibb Company Business Overview
- 8.8.3 Bristol-Myers Squibb Company Gastrointestinal Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Bristol-Myers Squibb Company Gastrointestinal Cancer Drugs Product Portfolio
- 8.8.5 Bristol-Myers Squibb Company Recent Developments
- 8.9 Celgene Corporation
- 8.9.1 Celgene Corporation Company Information
- 8.9.2 Celgene Corporation Business Overview
- 8.9.3 Celgene Corporation Gastrointestinal Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Celgene Corporation Gastrointestinal Cancer Drugs Product Portfolio
- 8.9.5 Celgene Corporation Recent Developments
- 8.10 Amgen & Amgen Ireland
- 8.10.1 Amgen & Amgen Ireland Company Information
- 8.10.2 Amgen & Amgen Ireland Business Overview
- 8.10.3 Amgen & Amgen Ireland Gastrointestinal Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Amgen & Amgen Ireland Gastrointestinal Cancer Drugs Product Portfolio
- 8.10.5 Amgen & Amgen Ireland Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Gastrointestinal Cancer Drugs Value Chain Analysis
- 9.1.1 Gastrointestinal Cancer Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Gastrointestinal Cancer Drugs Production Mode & Process
- 9.2 Gastrointestinal Cancer Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Gastrointestinal Cancer Drugs Distributors
- 9.2.3 Gastrointestinal Cancer Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst